{"id":"W2941356607","doi":"10.1097/01.ju.0000556757.85628.f0","title":"PD47-01 BMS-986205, AN INDOLEAMINE 2,3-DIOXYGENASE 1 INHIBITOR, PLUS NIVOLUMAB: UPDATED SAFETY ACROSS ALL TUMOR COHORTS AND EFFICACY IN ADVANCED BLADDER CANCER","year":2019,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Nivolumab; Indoleamine 2,3-dioxygenase; Bladder cancer; Oncology; Internal medicine; Cancer; Immunotherapy; Tryptophan","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001796793,0.000251912,0.0008143678,0.0005489526,0.0002153065,0.001105073,0.0003753846,0.0004422349,0.004592159],"category_scores_gemma":[0.001916381,0.0001630985,0.0007728555,0.0005642819,0.0001595398,0.0005670459,0.0002839402,0.001109383,0.00158352],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005566547,"about_ca_system_score_gemma":0.0008010662,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009038274,"about_ca_topic_score_gemma":0.001964423,"domain_scores_codex":[0.9993449,0.0001204765,0.0000620112,0.00006002988,0.0003471261,0.00006537557],"domain_scores_gemma":[0.9988548,0.0002437673,0.0002516977,0.00006507213,0.0004363092,0.0001484391],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.009248528,0.0006938497,0.01455781,0.001359081,0.0005644482,0.0001519973,0.00008786851,0.0006325796,0.01333651,0.000489291,0.1084056,0.8504725],"study_design_scores_gemma":[0.007725701,0.02218163,0.1303002,0.001357261,0.003639306,0.003656935,0.0002270477,0.004122773,0.03807602,0.001233801,0.7873132,0.0001661096],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.4799458,0.4062523,0.007579132,0.02298705,0.006555461,0.0005832639,0.0152599,0.002585247,0.05825185],"genre_scores_gemma":[0.7302552,0.1695159,0.01068895,0.01634277,0.005563891,0.0004021697,0.02325594,0.0004901412,0.04348493],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004592159,"threshold_uncertainty_score":0.01536226,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01323565038144977,"score_gpt":0.3069378680339613,"score_spread":0.2937022176525116,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}